General Information of This Metabolic Reaction (MR) (ID: MR013212)
Formula Reactant Remdesivir Alanine Metabolite (Ala-Met; GS-704277) Product Remdesivir Nucleoside Monophosphate
Reactant Info Product Info
Metabolic Type Oxidation - Deamination
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR013215 Remdesivir Remdesivir Alanine Metabolite (Ala-Met; GS-704277) Unclear Remdesivir [1]
MR013211 Remdesivir cyclic anhydride Remdesivir Alanine Metabolite (Ala-Met; GS-704277) Hydrolysis - Hydrolysis Remdesivir [2]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR009118 GS-441524 GS-441524-MP Unclear - Unclear GS-441524 [3]
MR013219 Remdesivir M1 Remdesivir Nucleoside Monophosphate Unclear Remdesivir [1]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR009119 GS-441524-MP GS-441524-DP Unclear - Unclear GS-441524 [3]
MR014046 Remdesivir Nucleoside Monophosphate GS-441524 Unclear Remdesivir [4]
MR014048 Remdesivir Nucleoside Monophosphate Remdesivir Nucleoside Triphosphate Conjugation - Phosphorylation Remdesivir [5]
MR013214 Remdesivir Nucleoside Monophosphate GS-441524 Unclear Remdesivir [2]
MR013213 Remdesivir Nucleoside Monophosphate Remdesivir Nucleoside Triphosphate Conjugation - Phosphorylation Remdesivir [2]
References
1 Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
2 Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
3 Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
4 Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction
5 Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.